HLA-DQA1*05 and HLA-DQA1*05/HLA-DQB1*02 Co-Carriage in Relation to Anti-TNF Antibody Concentrations and Response in Iraqi Patients with Inflammatory Bowel Disease

HLA-DQA1*05 has been associated with anti-TNF immunogenicity, but evidence from Iraqi patients remains limited. We explored associations of HLA-DQA1*05 and HLA-DQA1*05/HLA-DQB1*02 co-carriage with anti-drug antibody (ADAb) concentrations, trough concentrations, and response during maintenance treatment. This single-center cross-sectional analysis included 80 adults receiving infliximab (n = 41) or adalimumab (n = 39). Serum anti-TNF trough concentrations and ADAb levels were measured using an enzyme-linked immunosorbent assay. Real-time PCR detection of both targets defined unphased co-carriage. Drug-specific models used log concentrations with HC3 robust inference or logistic regression for response, adjusting for current azathioprine use. There were 55 HLA-DQA1*05 carriers, 20 haplotype co-carriers, and 38 responders. No adjusted primary or secondary genetic comparison met the multiplicity-adjusted significance threshold. Adjusted response odds ratios for HLA-DQA1*05 carriers were 0.29 (95% CI 0.06–1.36, p = 0.115) for infliximab and 1.35 (0.34–5.32, p = 0.670) for adalimumab; haplotype co-carriage estimates were 1.24 (0.26–5.78, p = 0.787) for infliximab and 0.63 (0.15–2.73, p = 0.540) for adalimumab. Exploratory component analysis found CRP < 5 mg/L in 15/29 infliximab DQA1*05 carriers versus 12/12 non-carriers (p = 0.003; q = 0.024). Neither the HLA-DQA1*05 genotype nor the HLA-DQA1*05/HLA-DQB1*02 haplotype provides evidence of significant associations with ADAb concentrations, serum trough levels, or therapeutic response in either infliximab- or adalimumab-treated patients (all p > 0.05). In this Iraqi IBD cohort, interpretation of estimates regarding the association of the HLA-DQA1*05 genotype and the HLA-DQA1*05/HLA-DQB1*02 haplotype should be expressed cautiously, and clinically meaningful associations cannot be excluded.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-19
DOI
https://doi.org/10.3390/ijms272210406
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

HLA-DQA1*05 and HLA-DQA1*05/HLA-DQB1*02 Co-Carriage in Relation to Anti-TNF Antibody Concentrations and Response in Iraqi Patients with Inflammatory Bowel Disease

Suha Saeed Azeez, Ban AbdulWahid Kanna
International Journal of Molecular Sciences
Inflammatory Bowel Disease
article

HLA-DQA1*05 and HLA-DQA1*05/HLA-DQB1*02 Co-Carriage in Relation to Anti-TNF Antibody Concentrations and Response in Iraqi Patients with Inflammatory Bowel Disease

Suha Saeed Azeez, Ban AbdulWahid Kanna
article en

Abstract

HLA-DQA1*05 has been associated with anti-TNF immunogenicity, but evidence from Iraqi patients remains limited. We explored associations of HLA-DQA1*05 and HLA-DQA1*05/HLA-DQB1*02 co-carriage with anti-drug antibody (ADAb) concentrations, trough concentrations, and response during maintenance treatment. This single-center cross-sectional analysis included 80 adults receiving infliximab (n = 41) or adalimumab (n = 39). Serum anti-TNF trough concentrations and ADAb levels were measured using an enzyme-linked immunosorbent assay. Real-time PCR detection of both targets defined unphased co-carriage. Drug-specific models used log concentrations with HC3 robust inference or logistic regression for response, adjusting for current azathioprine use. There were 55 HLA-DQA1*05 carriers, 20 haplotype co-carriers, and 38 responders. No adjusted primary or secondary genetic comparison met the multiplicity-adjusted significance threshold. Adjusted response odds ratios for HLA-DQA1*05 carriers were 0.29 (95% CI 0.06–1.36, p = 0.115) for infliximab and 1.35 (0.34–5.32, p = 0.670) for adalimumab; haplotype co-carriage estimates were 1.24 (0.26–5.78, p = 0.787) for infliximab and 0.63 (0.15–2.73, p = 0.540) for adalimumab. Exploratory component analysis found CRP < 5 mg/L in 15/29 infliximab DQA1*05 carriers versus 12/12 non-carriers (p = 0.003; q = 0.024). Neither the HLA-DQA1*05 genotype nor the HLA-DQA1*05/HLA-DQB1*02 haplotype provides evidence of significant associations with ADAb concentrations, serum trough levels, or therapeutic response in either infliximab- or adalimumab-treated patients (all p > 0.05). In this Iraqi IBD cohort, interpretation of estimates regarding the association of the HLA-DQA1*05 genotype and the HLA-DQA1*05/HLA-DQB1*02 haplotype should be expressed cautiously, and clinically meaningful associations cannot be excluded.

International Journal of Molecular SciencesVol. 27(22)
Hawler Medical University (IQ)
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon